Allowing evidence for “traditional use” could break the regulatory deadlock regarding health claims made for botanical food supplements, the European Commission has suggested. This would unlock innovation currently stunted by the “on hold” situation, note researchers Alie de Boer and Karin Lenssen in a paper for the European Parliamentary Research Services (EPRS). However, there are regulatory issues that would need to be resolved for this to work, they point out.
It’s time to decide whether evidence of “traditional use” for botanical ingredients can be used to substantiate health claims made for food in the European Union, argues a report recently published by the European Parliament.
Otherwise, the uncertainty produced by the current regulatory situation, in which over 2,000 botanical health claims are “on hold” while...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
